Jim Cramer: This Is The Right Time To Buy This Energy Stock

Jim Cramer recommended buying Phillips 66 (PSX) following its acquisition of the remaining 50% ownership in WRB Refining LP, and Cintas (CTAS) as a long-term hold ahead of its upcoming fiscal Q1 earnings. Conversely, he labeled Tandem Diabetes Care (TNDM) as speculative, despite an Outperform rating from Oppenheimer with a lowered price target, and indicated he would not invest in Intuitive Surgical (ISRG) despite its strong Q2 revenue and EPS beat. All four stocks, including PSX, CTAS, TNDM, and ISRG, experienced declines in Wednesday's trading session.

Analysis

The market is receiving mixed signals on several key stocks, driven by analyst commentary and corporate actions. For Phillips 66 (PSX), a bullish stance is supported by its strategic move to acquire the remaining 50% of the WRB Refining LP joint venture, which is seen as a positive catalyst despite the stock's minor 0.7% decline. Cintas (CTAS) is positioned as a long-term hold, with a recommendation to build a position ahead of its September 24th earnings report, suggesting confidence in its underlying business fundamentals. In contrast, Tandem Diabetes Care (TNDM) is framed as a high-risk, speculative play, a view reinforced by an Oppenheimer analyst who, while maintaining an 'Outperform' rating, slashed the price target by 50% from $44 to $22, contributing to the stock's 1.5% fall. The most notable divergence is with Intuitive Surgical (ISRG), where analyst hesitation is expressed despite the company reporting a significant second-quarter beat on both revenue ($2.44 billion vs. $2.35 billion estimate) and adjusted EPS ($2.19 vs. $1.93 estimate). The stock's subsequent 3.8% drop suggests investors may be prioritizing current sentiment and valuation concerns over strong recent performance.

Key Decisions for Investors

• Investors could view the dip in Phillips 66 as an entry point, given the fundamental catalyst provided by its full acquisition of the WRB Refining LP.
• For Cintas, a phased buying strategy could be prudent, initiating a position before the upcoming earnings and reserving capital to potentially add more on any post-release weakness.
• Tandem Diabetes Care warrants significant caution; its 'speculative' label and the severe price target cut signal high volatility, making it appropriate only for portfolios with a very high risk tolerance.
• The disconnect between Intuitive Surgical's strong Q2 earnings beat and the combination of analyst caution and a sharp share price drop suggests investors should scrutinize valuation and potential forward-looking headwinds before buying into the recent fundamental strength.